CLNN
Clene Inc.
There isn't enough reported data to score CLNN yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CLNN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CLNN's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CLNN PE Valuation
CLNN has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CLNN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CLNN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CLNN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.66 | +$1.01 |
| Q2 2026 | -$3.56 | +$0.48 |
| Q1 2026 | -$3.26 | +$1.06 |
| Q4 2025 | -$2.66 | +$3.37 |
| Q3 2025 | -$3.67 | +$2.35 |
| Q2 2025 | -$4.04 | +$1.16 |
| Q1 2025 | -$4.32 | +$5.62 |
| Q4 2024 | -$6.03 | +$5.11 |
CLNN is still losing money, but far less than before: $2.66 per share over the past year, against $17.63 at its worst in early 2021.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CLNN on earnings quality, reporting a profit while its opponent remains loss making.
CLNN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $56K | +273% |
| Q2 2026 | $90K | +233% |
| Q1 2026 | $15K | -81% |
| Q4 2025 | $77K | -15% |
| Q3 2025 | $15K | -83% |
| Q2 2025 | $27K | -70% |
| Q1 2025 | $81K | +11% |
| Q4 2024 | $91K | -46% |
CLNN's revenue is recovering but still below its 2023 peak: $56,000 last quarter, up 273% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -11334% | +26319 points |
| Q2 2026 | -5941% | +15777 points |
| Q1 2026 | -13740% | -8708 points |
| Q4 2025 | -9734% | -223 points |
| Q3 2025 | -37653% | -28671 points |
| Q2 2025 | -21719% | -13597 points |
| Q1 2025 | -5032% | +7615 points |
| Q4 2024 | -9511% | -3670 points |
CLNN's operating margin was −11334% last quarter, up 26319 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CLNN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CLNN on profitability, with a higher operating margin.
CLNN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.7M | -$665K |
| Q1 2026 | -$4.5M | +$483K |
| Q4 2025 | -$4.8M | +$39K |
| Q3 2025 | -$4M | -$979K |
| Q2 2025 | -$4.7M | +$1.6M |
| Q1 2025 | -$5M | +$2.1M |
| Q4 2024 | -$4.9M | +$2.3M |
| Q3 2024 | -$3M | +$3.8M |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with CLNN at up 38%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
CLNN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +18% | +2.3M shares |
| 1 year | +43% | +4.4M shares |
| 3 years | +128% | +8.2M shares |
| 5 years | +319% | +11.2M shares |
| Available history | +323% | +11.2M shares |
CLNN has 15M diluted shares, up 43% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over CLNN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CLNN Net Leverage
CLNN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CLNN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 36.9 | Neutral |
CLNN's weekly RSI is 44 (neutral) and its Stochastic is 37 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CLNN PE vs Healthcare Sector
| Metric | CLNN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CLNN has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CLNN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.88 | 3.1% above |
| 20 week MA | $4.47 | 11% below |
| 50 week MA | $5.23 | 24% below |
| 100 week MA | $5.19 | 23% below |
| 200 week MA | $8.40 | 52% below |
CLNN has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 52% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CLNN on trend strength, trading above more of its moving averages.
CLNN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $209.2 | $229.0 | +9.5% |
| 2021 | $229.0 | $87.4 | -62% |
| 2022 | $87.4 | $20.2 | -77% |
| 2023 | $20.2 | $5.93 | -71% |
| 2024 | $5.93 | $4.99 | -16% |
| 2025 | $4.99 | $6.25 | +25% |
| 2026 YTD | $6.25 | $4.00 | -36% |
CLNN has finished lower in four of the last six years. It's down 36% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CLNN on returns for 2026, with the stronger performance.